FCM
KIN

Farallon Capital Management’s Kindred Biosciences, Inc. KIN Stock Holding History

Farallon Capital Management’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-175,000
Closed -$1.62M – 101
2014
Q3 		$1.62M Hold
175,000
– – 0.03% 78
2014
Q2 		$3.26M Buy
+175,000
New +$2.97M 0.05% 82
2014
Q1 		– Sell
-82,445
Closed -$918K – 100
2013
Q4 		$918K Buy
+82,445
New +$983K 0.02% 77

Other funds holding KIN

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Farallon Capital Management's KIN Position: Q4 2014 in Review

Farallon Capital Management sold out of Kindred Biosciences, Inc. (KIN) in Q4 2014, closing a stake of 175,000 shares — an estimated $1.62M sold.

Farallon Capital Management first reported a position in KIN in Q4 2013 and held it in 3 quarters. The position peaked at $3.26M in Q2 2014. 64 funds tracked by Wall St. Rank hold KIN as of Q4 2014.

  • Farallon Capital Management reported no remaining Kindred Biosciences, Inc. position as of Q4 2014 after selling out during the quarter.
  • Farallon Capital Management sold 175,000 Kindred Biosciences, Inc. shares in Q4 2014, an estimated $1.62M.
  • Farallon Capital Management first reported a position in Kindred Biosciences, Inc. in Q4 2013 and held it in 3 quarters.
  • Farallon Capital Management's Kindred Biosciences, Inc. position peaked at $3.26M in Q2 2014.
  • 64 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q4 2014.

Based on Farallon Capital Management's 13F filing for Q4 2014, filed 17 Feb 2015.